Page 121 - Prostate News Today

Doctor, thank you. >> let me add one other thing. to say that even if our cases increase, which we expect thats going to happen around the nation, it does look like the omicron variant is more transmissible. our answer unlike other states is not more restrictions or more mandates. its really just early treatment. were going to be making sure thats known blanket or throughout the state. >> tucker: amen. thank you. good to see you, doctor. >> thanks, tucker. >> tucker: heres a piece of advice. if ...

Still talking about covid nonstop two years in, it is time to move. not just because your neighbors have been brainwashed but because your neighbors are boring. at this point it is simply not an interesting topic for your private life. yes, covid has killed a lot of people. so has prostate cancer. imagine people telling you about your prostate every day for the next two years. >> i dont even want to hear tucker use the word "prostate." dr. blackstock, you literally have somebody dismissing 800,0...

University of Michigan Regent Ron Weiser has committed $30 million to Michigan Medicine to establish an innovative, patient-focused program in prostate cancer.

An international research team co-led by scientists at Roswell Park Comprehensive Cancer Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has identified an important accelerator of treatment-resistant prostate cancer.

Surgeons at Henry Ford Health System's Vattikuti Urology Institute performed what is believed to be the first precision prostatectomy through the bladder using a single port robotic surgical system.

At the CRI Virtual Immunotherapy Patient Summit in October , patients and caregivers were eager to further their understanding of immunotherapy.

CHICAGO, Dec. 14, 2021 /PRNewswire/ -- According to the new market research report "Prostate Health Market by Disease Indication (Prostate Cancer, PARP Inhibitors, Cytotoxic Drug, Benign Prostate

It’s a question that has divided men’s health experts for years: Should healthy men, with no symptoms or family history of prostate cancer, get a prostate specific antigen test and treatment right away if a tumor is found?

A review assessed the impact of "hot" vs. "cold" immune/tumor environments (and associated therapies) on susceptibility and disease course in subjects with these two types of tumors and infected with SARS-CoV-2 to decipher the mechanisms that drive these adverse outcomes in COVID-19 infected cancer patients.

Men who have mutations in a gene called TP53 have a high risk of developing aggressive prostate cancer, a multicenter research team in the United States has found.